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Abstract
Background: Early diagnosis and treatment of HIV infection and suppression of viral load are potentially powerful
interventions for reducing HIV incidence. A test-and-treat strategy may have long-term effects on the epidemic among
urban men who have sex with men (MSM) in the United States and may achieve the 5-year goals of the 2010 National AIDS
Strategy that include: 1) lowering to 25% the annual number of new infections, 2) reducing by 30% the HIV transmission
rate, 3) increasing to 90% the proportion of persons living with HIV infection who know their HIV status, 4) increasing to
85% the proportion of newly diagnosed patients linked to clinical care, and 5) increasing by 20% the proportion of HIV-
infected MSM with an undetectable HIV RNA viral load.
Methods and Findings: We constructed a dynamic compartmental model among MSM in an urban population (based on
New York City) that projects new HIV infections over time. We compared the cumulative number of HIV infections in 20
years, assuming current annual testing rate and treatment practices, with new infections after improvements in the annual
HIV testing rate, notification of test results, linkage to care, initiation of antiretroviral therapy (ART) and viral load
suppression. We also assessed whether five of the national HIV prevention goals could be met by the year 2015. Over a 20-
year period, improvements in test-and-treat practice decreased the cumulative number of new infections by a predicted
39.3% to 69.1% in the urban population based on New York City. Institution of intermediate improvements in services
would be predicted to meet at least four of the five goals of the National HIV/AIDS Strategy by the 2015 target.
Conclusions: Improving the five components of a test-and-treat strategy could substantially reduce HIV incidence among
urban MSM, and meet most of the five goals of the National HIV/AIDS Strategy.
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Introduction
Men who have sex with men (MSM) represent about 2% of the
U.S. population [1] but accounted for 57% of new HIV diagnoses
in 2009. In addition, MSM with a history of injection drug use
accounted for another 3% of new diagnoses [2]. Not only are MSM
the population most severely affected by HIV, they are the only risk
group in which new HIV infections have been increasing steadily
since the early 1990s [3]. A 2008 surveillance project employing
venue-based sampling found that one in five (19%) MSM in 21
major U.S. cities were infected with HIV [4]. In addition, nearly
half (44%) were unaware of their infection and 55% had not been
tested for HIV infection in the previous 12 months.
Several modeling studies have shown that a test-and-treat
approach to HIV infection, whereby at-risk individuals are tested
frequently and linked to early treatment if diagnosed, could reduce
HIV epidemics [5]. One dynamic transmission model of males
and females suggested that a strategy of universal screening with
immediate initiation of effective antiretroviral therapy could
virtually eliminate the HIV epidemic in South Africa within 50
years [6]. Results from a similar dynamic transmission model of
MSM and injection drug users indicated that expanding access to
antiretroviral treatment, including earlier initiation of antiretrovi-
ral therapy (ART) (i.e., at a CD4 count of 350 versus 200 cells/
mm
3) could substantially reduce the HIV epidemic in British
Columbia, Canada [7]. A dynamic model based on San Francisco
MSM also showed improvement from earlier initiation of ART
therapy [8].
However, an individual simulation model of test-and-treat for
males and females in Washington, D.C., showed a modest impact
on HIV transmission over the next 5 years [9]. A dynamic
transmission model that explored the implications for low- and
high-risk U.S. populations of males and females also showed more
modest levels of improvement in HIV incidence over time [10].
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We used a dynamic mathematical model to estimate the
potential benefit of a proposed test-and-treat strategy to reduce
new HIV infections among MSM in an urban population. We
evaluated, singly and in combination, a set of five interventions
that could comprise a test-and-treat strategy: routine repeated
HIV screening, notification of results, linkage of HIV-infected
persons to care, initiation of treatment, and HIV viral load
suppression, defined as undetectable viral load based on the limits
of detection. We estimated the effect of these interventions as
currently practiced on the incidence of new HIV infections, and
then explored the same effects if these interventions were
implemented with intermediate, potentially feasible, levels of
improvement and then with maximum (best-case) levels of
improvement. We included these idealistic, best-case scenarios to
indicate the maximum number of new HIV cases that could be
prevented over time and to compare the extent to which more
feasible programmatic goals might achieve comparable results.
The 2010 U.S. National HIV/AIDS Strategy sets goals for
addressing the HIV epidemic by 2015 that include: 1) lowering by
25% the annual number of new infections, 2) reducing by 30% the
HIV transmission rate, 3) increasing to 90% the proportion of
persons living with HIV infection who know their HIV status, 4)
increasing to 85% the proportion of newly diagnosed patients
linked to clinical care, and 5) increasing by 20% the proportion of
HIV-infected gay and bisexual men with an undetectable HIV
RNA viral load [11]. We assessed the ability of our five-part test-
and-treat strategy – using values representing both intermediate
and best-case improvements in current practice – to reduce the
HIV epidemic in urban MSM over 20 years and to achieve
national HIV goals by 2015.
Methods
Dynamic compartment model
We constructed a dynamic compartmental model of HIV
infections among an urban population of MSM (based on New
York City). Our model included only sexual transmission of HIV
infection between MSM; it did not include MSM who are also
injection drug users.
Our model’s parameters for behavior, incidence, and treatment
were derived from data in CDC’s National HIV Behavioral
Surveillance System (NHBS), the New York City HIV/AIDS
Reporting System (HARS), and the CDC-sponsored HIV
Outpatient Study (HOPS). The New York City HARS is a
state-required registry. The NHBS and HOPS obtained written,
informed consent from participants. For NHBS the participants
were anonymous. The data we analyzed were extracted from
original datasets. Data extracts from all sources were stripped of
any elements that could identify individuals. We explained our
purpose in requesting the data to the data managers, but were not
required to obtain ethics approval from an ethics committee or
review board.
NHBS is used to monitor prevalence and trends in HIV-related
risk behaviors, HIV testing, and use of HIV prevention services
among populations at high risk for acquiring HIV. In 2008, NHBS
among MSM (NHBS-MSM2) collected venue-based sampling
data from 21 metropolitan statistical areas (MSAs) using an
anonymous cross-sectional interview of men at venues where
MSM congregate, such as bars, clubs, and social organizations.
Respondents gave written, informed consent for the interview and
were offered anonymous HIV testing, regardless of self-reported
HIV infection status [4]. The New York City HARS is a
population-based registry required by New York State that collects
dates of HIV diagnosis and initial and subsequent CD4 cell counts
for New York City residents who are diagnosed with HIV
infection [12]. The HOPS is a prospective longitudinal cohort
study of HIV-infected adults in care, many of whom are receiving
antiretroviral treatment, seen at urban HIV specialty clinics in the
United States that participated in the study. The study protocol is
approved annually by each participating clinic’s institutional
review board. All study participants provide written, informed
consent. The HOPS includes data on HIV RNA viral load, CD4
cell count, and treatment regimens over time for each patient
[13,14].
We divided the MSM population into compartments according
to five infection states, five age groups, and two sexual activity
levels based on the number of partners an individual had in a year.
The technical appendix (Appendix S1) contains more complete
details regarding our model and methods. Table 1 lists key
parameters used in the model, their values, and their sources. The
modeled infection states included HIV-uninfected MSM, who are
assumed to become HIV-infected through anal intercourse based
on the likelihood of forming a partnership with an infected person
and the probability of HIV transmission within that partnership.
Once infected, an individual was assumed to progress through the
stages of acute infection, early latent infection, latent infection, late
infection, and AIDS. At each infection state, HIV-infected
individuals may become aware of their infection through testing,
and linked to care. HIV-infected individuals in care received or
did not receive ART, with probability of ART initiation at a given
level of CD4 cell count derived from estimates in the HOPS. The
infection states corresponded to CD4 cell counts: early latent
infection to a CD4 count greater than 500 cells/mm
3, latent
infection to a CD4 count between 350 and 500 cells/mm
3, late
infection to a CD4 count between 200 and 350 cells/mm
3, and
AIDS to a CD4 count less than 200 cells/mm
3.
We used per-contact transmission probabilities from a study of
protected and unprotected, insertive and receptive anal inter-
course among MSM [15]. We modified those transmission
probabilities to obtain per-contact transmission probabilities by
each stage of infection using estimates in an observational study of
treatment-naı ¨ve couples engaged in heterosexual intercourse [16].
(Appendix S1.) Other studies have shown that transmission rates
from anal sex are similar overall for heterosexual and MSM
groups, but MSM transmission rates by disease state have not been
published [17]. We estimated the rate of transition from one stage
of infection to another from an observational study [16].
Individuals in the various age groups (i.e., 18–24, 25–34, 35–44,
45–54, and 55–64 years) entered the sexually active population
each year by aging, initiating sex with other men or immigrating
into the New York City geographic area. Individuals left the
modeled population due to older age, HIV/AIDS-related death,
or death from non-HIV/AIDS causes.
For the period before 2009, we used published guidelines to
inform our assumption about the timing of initiation of ART.
Initiation was generally recommended at CD4,350 cells/mm
3.
Since December 2009, treatment generally has been recom-
mended at CD4,500 cells/mm
3 and was recommended or
considered optional at CD4.500 cells/mm
3 [18]. However, for
2009 and beyond, we estimated the current practice average CD4
count for initiation of treatment using data from the HIV
Outpatient Study. Survival estimates for individuals receiving
ART depended on age and CD4 cell count at ART initiation
[19,20].
We validated our model against epidemic data from the
Department of Mental Health and Hygiene in New York City.
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group of uninfected MSM and the rate that persons exited from
sexual activity by calibrating our estimates to each age group’s
reported population in 2004. Then we fit a least squares curve to
reported diagnoses in AIDS from 1996–2008 based on surveil-
lance data from New York City. The percentage of the population
by age and activity already infected with HIV at the start of the
simulation in 1975 was selected to provide the best least squares fit.
The effects of HIV testing and awareness of HIV-positive status
on reducing secondary HIV transmission were based in part on
our assumption that diagnosed individuals decrease risky behav-
iors that could transmit HIV infection to their sexual partners. In
our model, persons who were diagnosed with HIV infection
decreased their number of sexual acts with HIV-uninfected
partners by 15% but kept the total number of sexual acts the
same [21]. They increased their use of condoms for anal sex from
50% to 75% [22–26]. We assumed a condom efficacy of 85% per
sexual act [27–31] and varied assumptions about condom use in
sensitivity analyses.
The prevalence of male circumcision is important for an MSM
model in the United States. We estimated prevalence at 60% [32].
Circumcision reduces the insertive infectivity for uninfected MSM
by 60%, based on results from three randomized controlled trials
in Africa on the efficacy of circumcision in preventing female-to-
male HIV transmission [33–35].
Interventions for a test-and-treat strategy
We evaluated the effect on the MSM HIV epidemic of a set of
five interventions that could be included in a future test-and-treat
strategy, both individually and combined. Those interventions
included an increased annual HIV testing rate, improved
notification of test results, improved linkage to care, earlier
initiation of ART and more complete achievement of HIV viral
load suppression. We established a current practice estimate for
Table 1. Values for input parameters for the model and references.
Description Of Parameter Value Range
Epidemiological parameters
Condom efficacy, [27–30] 85%
Reduction in HIV transmission among persons with suppressed viral load compared with
unsuppressed, [40]
90% 80%–99%
Percent of HIV+ who know their status: Age 18–24, [4] 0.319
Percent of HIV+ who know their status: Age 25–34, [4] 0.451
Percent of HIV+ who know their status: Age 35–44, [4] 0.626
Percent of HIV+ who know their status: Age 45–54, [4] 0.741
Percent of HIV+ who know their status: Age 55–64, [4] 0.763
Fraction unwilling to be tested until AIDS, [4] 5%
Behavioral parameters
Percent of the time using condoms for unaware, [22–26] 50%
Percent of the time using condoms for aware, [22–26] 75%
Fraction serosorting among aware, [21] 15%
Unprotected MSM per-contact transmission probability by disease state of HIV+ partner
Acute, HIV-uninfected receptive* 0.0560
Early Latent and Latent (Asymptomatic), HIV-uninfected receptive* 0.0048
Late (Symptomatic), HIV-uninfected receptive* 0.0096
AIDS, HIV-uninfected receptive* 0.0294
Acute, HIV-uninfected insertive* 0.0123
Early Latent and Latent (Asymptomatic), HIV-uninfected insertive* 0.0011
Late (Symptomatic), HIV-uninfected insertive* 0.0021
AIDS, HIV-uninfected insertive* 0.0065
Population parameters
Population of sexually active MSM in 2004** 194,000
Test-and-treat Interventions
Annual testing rate 24% 48%–95%
Notification rate for conventional testing 80% 90%–100%
Percent linked to care in 12 months 70% 85%–100%
Retention in care, [39] 85% 100%
Percent achieving viral load suppression 80% 90%–98%
Initiate treatment with ART CD4 300 cells/mm
3 CD4 500 cells/mm
3 or at diagnosis
*Calculated in Appendix S1.
**Calculated from New York City Community Health Survey.
doi:10.1371/journal.pone.0029098.t001
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intermediate and best-case levels of improvement in current
practice. The best-case levels of improvement were very optimistic
while the intermediate levels of improvement were roughly mid-
way between current and best-case levels and may be more
feasible in practice. Parameters used for each intervention
included in our test-and-treat strategies are listed in Table 1.
Annual rates of testing for HIV infection
We estimated an annual testing rate that produced the annual
number of newly diagnosed MSM with AIDS (CD4 count less
than 200 cells/mm
3) in New York City in 1997–2009 [36] and
produced the estimated percent of infected individuals (by age
group) aware of their infection in 2008 [4]. The estimated overall
annual testing rate was 24% per year for persons who were HIV-
infected, unaware of their infection, and willing to be tested; but
the rate varied by age and infection state – our model assumed
persons not HIV-infected were tested at the same rate. HIV-
infected individuals who were older or who were at a more
advanced stage of HIV disease were more likely to be tested and
diagnosed than were younger persons or persons with less
advanced HIV disease. We examined the benefits of increasing
the annual testing rate to an intermediately effective value of 48%
and a best-case effective value of 95%. In all analyses we assumed
that 5% of HIV-infected MSM would not be tested until they had
a CD4 count less than 200 cells/mm
3 [4].
Notification of test results
An individual who was tested must be notified of the result and
linked to care to benefit from a test-and-treat strategy. We
assumed that each year half of the tested persons were tested using
rapid point-of-care tests and that all of those newly diagnosed with
HIV infection received their results. We assumed that the
remaining half were tested with conventional tests and that 80%
of those newly diagnosed with HIV received their results [37,38].
We examined the benefit of improving notification of a positive
result following a conventional test to 90% and 100%, in both the
intermediate and best cases, respectively.
Linkage to care and retention in care
We estimated 70% of MSM who tested positive were linked to
care in the first year [39]. Diagnosed persons not linked to care in
the first year were given a 10% annual probability of linkage in each
subsequent year until they reached AIDS, or a CD4 count of 200
cells/mm
3, at which time they had 100% probability of linkage to
care. We assumed an annual 15% drop-out-of-care rate among
individuals who had been linked to care but had not initiated ART
[40]. We assumed an annual 10% reentry-to-care rate among
individuals who had been linked to care but had dropped out before
ART initiation. Once their CD4 count declined to 200 cells/mm
3,
all individuals were assumed to be relinked. We considered 100%
retention in care in a sensitivity analysis.
We examined the benefits of improving linkage to care in the
first year to an intermediate value of 85% (consistent with the
National HIV/AIDS Strategy 2015 target) and a best-case value
of 100%. Persons had to be in care to initiate ART.
Initiation of ART
We estimated current practice for ART initiation based on CD4
cell count at initiation in the HIV Outpatient Study. For 2004–
2009, the median and mean CD4 counts at ART initiation were
300.0 cells/mm
3 and 299.9 cells/mm
3 respectively for 381 MSM
who had a CD4 cell count available. Of those 381 MSM initiating
ART, 29.1% had CD4 counts less than 200 cells/mm
3, 34.6% had
CD4 counts between 200 and 349 cells/mm
3, 23.4% had CD4
counts between 350 and 499 cells/mm
3, and 12.9% had CD4
counts of 500 cells/mm
3 or greater. We examined the effect of
starting ART at 500 cells/mm
3 as an intermediate case, and at
diagnosis (regardless of CD4 cell count level) as a best case.
Persons already in care but not receiving ART also started ART at
these new levels.
Viral load suppression
We estimated that 80% of persons who started ART achieved
viral load suppression, defined as undetectable viral load based on
the limit of detection. This estimate took into account retention in
care, adherence to treatment and the immune response to
treatment [41]. We examined 90% viral load suppression in the
intermediate case and 98% in the best case [42].
We further assumed that persons who achieved viral load
suppression experienced a 90% decline in the rate of per-contact
HIV transmission compared with persons who do not achieve viral
load suppression [43,44]. In sensitivity analysis, we varied that
assumption from an 80% to a 99% decline in the rate of per-
contact transmission.
Analysis plan
We simulated annual testing rates, notification of results, linkage
to care, initiation of treatment and viral load suppression for the
time frame 1996 to 2009 to project future trends based on our
current practice. We projected trends from 2010 through 2029
and applied our set of test-and-treat interventions to current
practice improved to both intermediate and best-case levels. We
also examined the projected number of new HIV infections and
other model outcomes for the year 2015, comparing current with
improved practices, to determine if our proposed test-and-treat
strategy could meet the National HIV/AIDS Strategy goals for
urban MSM. We estimated the impact of each intervention
separately and of all interventions combined.
We performed sensitivity analyses that considered risk compen-
sation to determine the consequences if individuals receiving ART
(regardless of HIV RNA viral load) decided not to continue using
condoms with the same frequency [45]. We determined the
threshold value for the decline in condom use among all infected
and uninfected MSM that would eliminate all benefits of our
proposed test-and-treat strategy, assuming only intermediate levels
of improvement to the individual interventions. We considered the
‘‘high risk’’ scenario where individuals on ART stopped using
condoms [46].
Although retention in care is not explicitly part of the National
HIV/AIDS Strategy goals, we considered the effect of improving
retention in care among persons not receiving ART from 85% to
100%.
Results
Reduction in new infections using proposed test-and-
treat strategy
Under our estimated current practice for annual HIV testing,
notification of results, linkage to care, initiation of ART and viral
load suppression, our model projected that 53,178 cumulative new
HIV infections would occur in this population of MSM over the
next 20 years (Table 2). This projection was associated with an
increase in prevalence from 15.0% in 2010 to 18.3% in 2029
(Figure 1). Our prevalence estimate falls between that of 13.7%
(95% C.I. 6.0%–28.3%) based on 55 MSM from the New York
City Health and Nutrition Examination Survey 2004 [47] and
A Mathematical Model of Test-and-Treat Services
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e2909829% (95% C.I. 25%–33%) based on 462 MSM in New York City
in NHBS-MSM2 2008 [4].
When all interventions were simultaneously implemented at
intermediate levels of improvement (including beginning ART at a
CD4 count of 500 cells/mm
3), compared with the base case, the
projected cumulative number of new HIV infections over 20 years
was 32,284, a 39.3% reduction. Among the individual interven-
tions, those with the largest effect on reducing cumulative new
infections over 20 years were increasing the annual testing rate
among HIV-infected MSM from 24% to 48% (associated with
15.3% fewer infections), increasing viral load suppression among
persons receiving ART from 80% to 90% (associated with 10.8%
fewer infections) and initiating ART at a CD4 count of 500 cells/
mm
3 (associated with 8.5% fewer infections) (Table 2).
Under intermediate levels of improvement for all interventions,
the prevalence of HIV infections in 2029 was reduced from 18.3%
to 13.3%. (Figure 1), and the annual number of new HIV
infections in 2029 was reduced from 2,661 under base case
estimates to 1,355 (a 49.1% reduction) (Figure 2).
When all five interventions were simultaneously implemented at
best-case levels of improvement (including beginning ART at HIV
diagnosis), compared with the base case, the cumulative number of
new infections over 20 years was 16,411, a 69.1% reduction. For
single interventions each implemented to best-case levels of
improvement, reductions in new infections over 20 years ranged
from 22.7%, for an increase in the annual testing rate, to 1.8%, for
increased notification (Table 2). The prevalence of HIV infections
in 2029 was reduced to 8.7% (Figure 1), and the annual number of
Figure 1. Prevalence of HIV infections over 20 years for MSM in New York City, percent.
doi:10.1371/journal.pone.0029098.g001
Table 2. Reduction in new infections from HIV annual testing, notification, linkage to care, treatment, and viral load suppression.
Description
Intermediately
Effective Value for
Parameter
Total New
Infections Over
20 Years
% Decrease
Current
Practice
Best-case Effe-
ctive Value for
Parameter
Total New
Infections Over
20 Years
% Decrease
from Current
Practice
Current practice 53,178 53,178
Increase annual testing
rate, Current=24%
48% 45,035 15.3% 95% 41,085 22.7%
Increase notification, Current=80% 90% 52,686 0.9% 100% 52,230 1.8%
Increase linkage, Current=70% 85% 52,077 2.1% 100% 50,991 4.1%
ART Initiation Current=CD4
count of 300 cells/mm
3
CD4 count=500
cells/mm
3
48,674 8.5% At diagnosis 46,943 11.7%
Increased viral load suppression,
Current=80%
90% 47,453 10.8% 98% 42,521 20.0%
Combination of all interventions 32,284 39.3% 16,411 69.1%
doi:10.1371/journal.pone.0029098.t002
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reduction) (Figure 2).
National HIV/AIDS Strategy 2015 goals
Implementing our proposed set of test-and-treat interventions to
intermediate levels of improvement, including initiation of ART at
CD4 counts less than 500 cells/mm
3, would meet four of the five
National HIV/AIDS Strategy goals by 2015. The only unmet goal
was that of increasing to 90% the proportion of MSM living with
HIV who would know their status, due largely to the 5% of men
who are not tested until they progress to AIDS. With our
combination of interventions implemented to their best-case levels
of improvement, all five of the goals were met by 2015 (Table 3).
Sensitivity analyses
When we modeled implementation of intermediate levels of
improvement in each of the test-and-treat interventions, but
individuals receiving ART used condoms 50% of the time instead
of 75%, a 31.6% reduction in new HIV cases occurred over 20
years, compared with the 39.3% reduction we observed without
this proposed risk compensation. (Table 4) In the ‘‘high risk’’ case,
where individuals receiving ART stopped using condoms, there
was a 17.1% reduction in the number of new HIV infections.
Threshold analysis indicated that a decrease in condom use to
50% by all MSM (HIV-infected and not HIV-infected, receiving
ART and not receiving ART) would have eliminated nearly all of
the reduction in new infections associated with having imple-
mented our combination of test-and-treat interventions to
intermediate levels of improvement (Table 4).
When each of the interventions in our proposed test-and-treat
strategy were implemented to intermediate levels of improvement,
but the reduction in the per-contact transmission rate risk was
80% instead of 90% among MSM with viral load suppression,
then the reduction in new cases over 20 years was 26.4% (Table 4)
compared with 39.3% (Table 2). When the reduction in per-
contact transmission rate was 99% instead of 90%, reduction in
new infections was 51.6%.
When annual retention in care was increased from 85% to
100%, the reduction in cumulative new HIV infections over 20
years with intermediate and best-case levels of improvement in
each intervention in the proposed test-and-treat strategy were
45.1% (from 39.3%) and 72.3% (from 69.1%), respectively
(Table 4).
Discussion
Using a dynamic, compartmental model our analysis indicated
that a five-component test-and-treat strategy such as we have
proposed might dramatically reduce new HIV infections over the
next 20 years within a heavily affected U.S. population, namely
urban MSM. Our strategy required implementing multiple
interventions to ensure widespread and frequent testing of the
at-risk populations and greater and more comprehensive provision
of treatment. Our analysis explored the effect of implementing
each intervention individually and combined to both intermediate
and best-case levels of improvement.
While improving each intervention individually had some effect,
the most significant impact resulted from improving all simulta-
neously. Even with intermediate levels of improvement in the
implementation of these interventions, their combination reduced
the cumulative number of new HIV infections over 20 years by
39.3% and reduced HIV prevalence from a projected 18.3% to
13.3%.
Among individual interventions, the most effective was
increasing the annual testing rate. Diagnosing previously undiag-
nosed HIV-infected individuals was associated with a substantial
reduction in risk behavior and enabled infected individuals to
enter care with the possibility of achieving viral load suppression.
However, attaining a 48% annual testing rate will likely require
Figure 2. Annual number of new HIV infections over 20 years for MSM in New York City.
doi:10.1371/journal.pone.0029098.g002
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outreach to the infected, undiagnosed.
Our findings suggest that initiating ART at the intermediate
CD4 count of 500 cells/mm
3, according to current guidelines,
could by itself have a substantial impact on HIV incidence,
reducing the expected number of new HIV infections by 8.5%
over 20 years. In comparison, initiation of treatment at diagnosis,
the best-case scenario, resulted in a reduction of 11.7% over 20
years. The fact that the bulk of the benefit was associated with the
intermediate case is not surprising considering that diagnosis, in
the base case, occurs on average at CD4 300 cells/mm
3, meaning
that few individuals would be diagnosed in time to start ART at
counts higher than 500 cells/mm
3.
Viral load suppression on ART, another important variable in
our test-and-treat strategy, required not only linkage, but also
retention in care, as well as adherence to treatment. Although
there is a fairly extensive literature on strategies to promote
adherence to antiretroviral therapy [48–50], less is known about
how to promote retention in care [51–53]. Meeting the
intermediate targets for earlier initiation of treatment and viral
load suppression may require an increased commitment to the
provision of treatment and to programs that maintain individuals
on treatment once they begin. Nearly 9,000 low-income
individuals with HIV were on waiting lists to receive treatment
in September 2011 [54,55]. A longitudinal study in Nigeria
showed that patients who started treatment at higher CD4
Table 4. Sensitivity analyses for MSM in New York City.
Intermediate levels of improvement to all interventions Best-case levels of improvement to all interventions
Scenarios
# of new infections
over 20 years
% change from
current practice
# of new infections
over 20 years
% change from
current practice
Current practice* 53,178 53,178
Combination of all interventions 32,284 39.3% 16.411 69.1%
50% condom use by persons
receiving ART
36,366 31.6% 20,861 60.8%
0% condom use by persons
receiving ART
44,091 17.1% 29,963 43.3%
50% condom use by everyone 53,053 2.4% 30,114 43.4%
80% reduction in per-contact trans-
mission under viral load suppression
39,166 26.4% 24,063 54.8%
99% reduction in per-contact trans-
mission under viral load suppression
25,748 51.6% 9,862 81.5%
100% retention in care 29,187 45.1% 14,709 72.3%
*The sensitivity analyses’ results are compared to the current practice in which HIV-infected MSM aware of their infection use condoms for 75% of sex acts, compared
with condom use for 50% of sex acts among persons who are HIV-infected but unaware of it. In addition, among HIV-infected MSM who achieve viral load suppression
receiving ART in the current practice analysis, per-contact transmission risk is reduced 90% compared to HIV-infected MSM whose viral load is not suppressed.
doi:10.1371/journal.pone.0029098.t004
Table 3. Test-and-treat for MSM in New York City and the National HIV/AIDS Strategy for the United States, 2015.
National 2015 goals/Results
for each intervention)
Annual Number
of New Infections
(Q25%)
HIV Transmission
Rate
(Q30%)
% MSM Living
with HIV and Aware
(90%)
% Newly Diagnosed
Linked to Care in 1 Year
(85%)
% Diagnosed with
Undetectable Viral Load
(q20%)
Current practice 2,657 8.56% 65.3% 70.0% 51.7%
Goal based on current practice 1,993 5.99% 90.0% 85.0% 62.0%
Increase annual testing rate from
24% to 48%
2,290 7.64% 81.0% 70.0% 46.6%
Increase conventional testing
notification from 80% to 90%
2,635 8.50% 66.1% 70.0% 51.5%
Increase linkage from 70% to 85% 2,616 8.41% 65.7% 85.0% 53.3%
ART at CD4 count=500 cells/mm
3 2,461 7.90% 67.1% 70.0% 59.1%
Increase viral load suppression
from 80% to 90%
2,407 8.03% 66.6% 70.0% 58.8%
All intermediately effective,
including ART at CD4
count=500 cells/mm
3
1,707 5.93% 84.5% 85.0% 63.2%
All best-case effective, including
ART at diagnosis
923 3.56% 93.6% 100% 86.3%
Figures in boldface indicate the intervention or combination of interventions that achieve each National HIV/AIDS Strategy goal.
doi:10.1371/journal.pone.0029098.t003
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non-adherence [56].
Implementing notification of test results and linkage to care to
intermediate levels of improvement led to a more modest
reduction in number of new HIV infections over 20 years (0.9%
and 2.1% respectively). The reduced impact of these interventions
seems to be due to already relatively high estimated notification
and linkage rates and thus more limited room for improvement. If
the proportion of persons tested with conventional testing is more
than our assumed 50%, then improved notification may be more
important. However, if the proportion of persons tested with rapid
testing is more than our assumed 50%, then notification will be
higher than our estimates; this may occur as rapid testing becomes
more widely used.
The results of our sensitivity analyses indicated that a reduction
in condom use to 50% from 75% among all urban infected MSM
negated the benefits of the intervention. This finding underscores
that safer sex practices such as condom use must be maintained in
the MSM community.
Published reports vary regarding reductions in HIV transmis-
sion associated with suppression of plasma HIV RNA viral loads.
By our estimate, even with an 80% reduction, a value that is at the
lower bound of reported estimates, implementation of a test-and-
treat strategy to intermediate levels of improvement could reduce
the number of new infections by 26.4% over 20 years. If we
assumed viral load suppression achieved a 99% reduction in the
risk of HIV transmission, then the number of new infections over
the same period was reduced by 51.6%. Our analyses conserva-
tively assume that ART confers a reduction in transmission only
when viral load suppression is achieved.
We also explored the ability of a test-and-treat strategy to
achieve the shorter-term goals laid out by the National HIV/
AIDS Strategy. We found that a combined test-and-treat strategy
such as the one we have proposed that achieves intermediate levels
of improvement in each intervention can meet four of the five
goals of the National HIV/AIDS Strategy. Thus, a multi-
component test-and-treat strategy could be a valuable part of
the National HIV/AIDS Strategy.
Other models forecasting the effect of test-and-treat strategies
on HIV epidemics in North America have been constructed and
parameterized somewhat differently than ours. Our results are
similar to those that assessed the impact of test-and-treat strategies
on new HIV infections in British Columbia, where a 37% to 62%
reduction in new cases over 25 years was estimated if the
proportion of eligible individuals who received ART increased
from 50% to 100% [7]. Another modeling exercise of the
epidemic in the United States indicated that a strategy of test-and-
treat could achieve an 18% reduction in new HIV infections over
20 years [10]. That model focused on low- and high-risk
populations and assumed more modest reductions in risky sexual
behaviors than we did (i.e., 20% vs. 50%) associated with the
diagnosis of HIV infection.
Our model extrapolated past trends and current conditions into
the future. If future conditions change with the emergence of more
effective behavioral or biomedical prevention strategies, then the
prevention benefit from the test-and-treat strategy we have
proposed would likely change as well. Further, the benefits of a
test-and-treat strategy as forecast by our model depend on correct
estimates of levels of current implementation. For example, the
timing of initiation of ART is an important parameter that we
estimated using data from a cohort of HIV-infected MSM
receiving care. However, this cohort may not be representative
of all HIV-infected MSM, particularly those with limited access to
care and persons who do not reside in metropolitan areas of the
U.S. Similarly, our estimate that 80% of persons who initiate ART
are able to achieve and maintain viral load suppression, likewise
taken from HIV-infected MSM in care, may be optimistic.
However, in both cases, our model likely underestimates the
benefits of a test-and-treat strategy.
We did not assess the potential effect of antiretroviral resistance.
Increases in the prevalence and transmission of antiretroviral
resistant HIV could reduce population-based responsiveness to
treatment that in turn reduces the effectiveness of a test-and-treat
strategy. Findings from a previously published modeling exercise
using population-level resistance data indicated that the effect of
antiretroviral resistance on the projected number of new HIV
cases was minimal [7].
Our analysis was based on New York City data. We assumed
that the analysis may extend to other urban areas in the United
States. However, for all estimates of current implementation, there
is likely to be variation by race, ethnicity, age and geography.
The findings from our model provide decision makers with
more information on how best to implement a test-and-treat
strategy among MSM, highlighting the importance of a multi-
pronged approach and allowing an assessment of which individual
interventions might be most important to the success of such a
strategy. It offers guidance based on reasonable implementation
targets. It indicates how implementation of our multi-component
test-and-treat strategy can attain the National HIV/AIDS Strategy
goals. Ideally, findings from this model will spur more research on
how best to improve implementation of the individual interven-
tions; particularly interventions that increase the annual HIV
testing rate and that improve adherence and retention in care.
Our model suggests that a test-and-treat strategy could have a
substantial impact on the urban MSM HIV epidemic, but would
not replace the need for consistent condom by MSM.
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